← All trials
NCT04722146
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2021
- Primary completion
- Oct 11, 2022
- Completion date
- Nov 1, 2023
- First posted
- Jan 25, 2021
- Last posted
- Nov 5, 2021
- Enrollment
- 140
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Johnson and JohnsonStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.